|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 479.51 USD | -2.00% |
|
-0.09% | +35.90% |
| 12-08 | United Therapeutics Insider Sold Shares Worth $3,870,056, According to a Recent SEC Filing | MT |
| 12-05 | United Therapeutics Insider Sold Shares Worth $3,821,130, According to a Recent SEC Filing | MT |
| Capitalization | 20.65B 17.77B 16.68B 15.51B 28.59B 1,861B 31.19B 194B 75.28B 879B 77.49B 75.83B 3,220B | P/E ratio 2025 * |
17.7x | P/E ratio 2026 * | 16.8x |
|---|---|---|---|---|---|
| Enterprise value | 17.58B 15.13B 14.2B 13.2B 24.34B 1,585B 26.55B 166B 64.09B 748B 65.97B 64.55B 2,741B | EV / Sales 2025 * |
5.48x | EV / Sales 2026 * | 4.79x |
| Free-Float |
58.58% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: United Therapeutics Corporation
| 1 day | -2.00% | ||
| 1 week | -0.09% | ||
| Current month | -1.34% | ||
| 1 month | +6.82% | ||
| 3 months | +21.51% | ||
| 6 months | +47.17% | ||
| Current year | +35.90% |
| 1 week | 470.13 |  | 489.99 |
| 1 month | 445.81 | | 492.62 |
| Current year | 266.98 | | 492.62 |
| 1 year | 266.98 | | 492.62 |
| 3 years | 204.44 | | 492.62 |
| 5 years | 131.04 | | 492.62 |
| 10 years | 74.31 | | 492.62 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 70 | 25/06/1996 | |
| President | 53 | 25/06/2016 | |
James Edgemond
DFI | Director of Finance/CFO | 57 | 12/03/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Raymond Kurzweil
BRD | Director/Board Member | 77 | 31/12/2001 |
| Chairman | 70 | 25/06/1996 | |
Louis Sullivan
BRD | Director/Board Member | 91 | 31/12/2001 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 3.06% | 1 M€ | 0.00% | - |
| 2.87% | 2 M€ | -.--% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -2.00% | -0.09% | +29.71% | +71.33% | 21.07B | |
| -1.26% | -5.70% | +20.67% | +168.32% | 905B | |
| -0.15% | -1.81% | +35.03% | +13.78% | 487B | |
| -1.31% | -0.88% | +26.64% | +34.42% | 400B | |
| +2.19% | +2.82% | +23.62% | +4.87% | 330B | |
| -0.10% | -1.86% | +27.45% | +19.99% | 281B | |
| -0.41% | +2.28% | +18.74% | +25.02% | 255B | |
| -0.79% | -2.85% | -4.04% | -10.75% | 248B | |
| -3.42% | -4.91% | -61.94% | -33.36% | 214B | |
| -2.63% | -4.82% | +17.85% | +12.49% | 178B | |
| Average | -1.01% | -1.78% | +13.37% | +30.61% | 331.76B | |
| Weighted average by Cap. | -0.81% | -2.42% | +16.94% | +54.33% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 3.21B 2.76B 2.59B 2.41B 4.44B 289B 4.84B 30.19B 11.69B 136B 12.03B 11.78B 500B | 3.39B 2.92B 2.74B 2.55B 4.69B 306B 5.12B 31.93B 12.36B 144B 12.73B 12.45B 529B |
| Net income | 1.3B 1.12B 1.05B 977M 1.8B 117B 1.97B 12.25B 4.74B 55.38B 4.88B 4.78B 203B | 1.36B 1.17B 1.1B 1.02B 1.88B 122B 2.05B 12.79B 4.95B 57.82B 5.1B 4.99B 212B |
| Net Debt | -3.07B -2.64B -2.48B -2.31B -4.25B -277B -4.64B -28.91B -11.19B -131B -11.52B -11.27B -479B | -4.39B -3.78B -3.55B -3.3B -6.08B -396B -6.64B -41.36B -16.02B -187B -16.49B -16.13B -685B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 08/12/25 | 479.51 $ | -2.00% | 468,637 |
| 05/12/25 | 489.31 $ | +1.08% | 303,006 |
| 04/12/25 | 484.10 $ | +0.65% | 630,755 |
| 03/12/25 | 480.96 $ | +1.44% | 301,473 |
| 02/12/25 | 474.14 $ | -1.21% | 308,992 |
Delayed Quote Nasdaq, December 08, 2025 at 09:00 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- UTHR Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition